Clinical Trial Update: BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating BGB-A3055 alone and in combination with tislelizumab for solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BGB-A3055
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: TERMINATED